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Abstract: Vitamin B12 is often used to improve cognitive function, depressive symptoms, and
fatigue. In most cases, such complaints are not associated with overt vitamin B12 deficiency or
advanced neurological disorders and the effectiveness of vitamin B12 supplementation in such
cases is uncertain. The aim of this systematic review and meta-analysis of randomized controlled
trials (RCTs) is to assess the effects of vitamin B12 alone (B12 alone), in addition to vitamin B12
and folic acid with or without vitamin B6 (B complex) on cognitive function, depressive symptoms,
and idiopathic fatigue in patients without advanced neurological disorders or overt vitamin B12
deficiency. Medline, Embase, PsycInfo, Cochrane Library, and Scopus were searched. A total of 16
RCTs with 6276 participants were included. Regarding cognitive function outcomes, we found no
evidence for an effect of B12 alone or B complex supplementation on any subdomain of cognitive
function outcomes. Further, meta-regression showed no significant associations of treatment effects
with any of the potential predictors. We also found no overall effect of vitamin supplementation on
measures of depression. Further, only one study reported effects on idiopathic fatigue, and therefore,
no analysis was possible. Vitamin B12 supplementation is likely ineffective for improving cognitive
function and depressive symptoms in patients without advanced neurological disorders.
Keywords: vitamin B12; cognitive function; depressive symptoms; fatigue; RCT; meta-analysis
1. Introduction
Declines in cognitive function, depressive symptoms, and idiopathic fatigue (fatigue
of unknown cause) are highly prevalent in the general population [1–9]. The illnesses un-
derlying these symptoms are often unknown and treatment options are scarce, with a focus
on nutrient supplements [10]. There is a potential causal association between these highly
prevalent mental symptoms and low serum levels of B vitamins [11]. Pyridoxine (vitamin
B6), folic acid (vitamin B9), and cobalamin (vitamin B12) are necessary cofactors for the
synthesis of myelin and neurotransmitters [12–17]. A decrease in levels of these vitamins is
associated with elevated homocysteine levels, risk of cognitive impairment [18–23], and
depression [24,25]. The main cause of decreases in vitamin B12 serum levels is enteral mal-
absorption, primarily in the elderly due to gastric atrophy [26,27]. Mere food fortification is
insufficient in this situation but high-dose oral or parenteral supplements increase vitamin
B12 serum levels [28,29].
Diagnostic thresholds for vitamin B12 serum levels differ between countries and
laboratories. For deficiency, serum levels below 148 pmol/L are most often used [14].
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Subclinical vitamin B12 deficiency refers to serum levels above 148 pmol/L and the thresh-
olds defining vitamin B12 adequacy are still debated. In people aged 60 years or older,
the prevalence of vitamin B12 deficiency is about 5–6% and the prevalence of subclinical
vitamin B12 deficiency is 20–25% [30,31]. The role of vitamin B12 “replacement” which
applies to patients with unambiguous vitamin B12 deficiency as in pernicious anemia
is undisputed. However, the role of vitamin B12 “supplementation” which applies to
patients with subclinical or normal vitamin B12 serum levels is less clear. Considering
the association of subclinical vitamin B12 serum levels with declines in cognitive function,
depressive symptoms, and fatigue, vitamin B12 supplementation appears to be a promising
treatment option. Therefore, physicians often prescribe vitamin B12 to improve mental out-
comes across a broad range of vitamin B12 serum levels, including subclinical and normal
levels. The current popularity of vitamin B12 supplementation is reflected by a recently
published study from Canada, reporting that up to 60% of vitamin B12 prescriptions are
given to patients aged 65 years or older with normal or undocumented vitamin B12 serum
levels [32].
To date, several randomized trials (RCTs) and a few systematic reviews on B vitamins
for mental outcomes have been published. Most of the original studies and systematic re-
views have provided little support to continuing supplementation of B vitamins for improv-
ing mental outcomes; however, the applicability of the results in clinical practice is limited.
This is because the former reviews included original studies, which included patients with
advanced neurological disorders, leading to heterogeneous patient populations [33–50],
or even focused exclusively on such patients [50]. Thereby, previous systematic reviews
have provided little support for physicians, whose patients with mental ailments typically
do not present detectable cerebral disease, and hence, vitamin B12 supplementation may
still be an effective treatment option. Further, most systematic reviews have also included
trials investigating folic acid alone, introducing heterogeneity at the treatment level, not
considering the specific role of vitamin B12 [33–35,38,39,41,42,44,45,47–51].
The aim of this systematic review and meta-analysis of RCTs was to assess the effects
of vitamin B12 supplementation—alone and in combination with folic acid—on cognitive
function, depressive symptoms, and idiopathic fatigue, in patients without advanced
neurological disorders.
2. Materials and Methods
This systematic review followed the guidelines of the “Preferred Reporting Items for
Systematic Reviews and Meta-Analyses” (PRISMA) [52] and was registered at Prospero
(CRD42019135823).
2.1. Data Sources and Search Strategy
An experienced librarian (S.K.) at Careum Bibliothek of the University of Zurich
(Zurich, Switzerland) conducted a systematic literature search in June 2020. The following
six databases were included: MEDLINE® (via Ovid), Embase®, PsycINFO, Cochrane Li-
brary, and Scopus. The following search terms among others were used: “vitamin B12”,
“cyanocobalamin”, “methylcobalamin”, “hydroxycobalamin”, “cognition”, “cognitive im-
pairment”, “cognitive function”, “memory”, “depression”, “depressive”, and “fatigue”.
A detailed description of all search strategies is provided in Supplementary Table S1. In
addition, we searched the clinical trial registries ClinicalTrials.gov, International Clinical
Trials Registry Platform (ICTRP), EU Clinical Trial Register, and the ISRCTN registry for
ongoing or unpublished trials. No search limitations were applied in terms of publication
date or language. Further, reference lists from reviews and meta-analyses were manually
scanned to identify any other relevant studies.
2.2. Criteria for Study Inclusion/Exclusion
We included RCTs that investigated the therapeutic effects of vitamin B12 alone (B12
alone) and vitamin B12 in addition to vitamin B9 (folic acid) with or without vitamin B6 (B
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complex) on measures of cognitive function, depressive symptoms, and fatigue in patients
with or without mild cognitive impairment (MCI). Eligible studies had to be double-blind
and placebo-controlled with at least 20 participants aged 18 years or older per study group;
administered a daily defined dose (DDD) of at least 100 mcg vitamin B12 either orally or
intramuscularly. Studies were excluded if they were directed at patients with neuropathy
following overt vitamin B12 deficiency (thus, studying vitamin B12 “replacement” and not
“supplementation”), advanced neurological disorders (e.g., Alzheimer’s disease, dementia,
or stroke), major depression or psychotic disorders (e.g., schizophrenia, psychosis); targeted
highly specialized patient groups (e.g., with end-stage renal disease only, chronic intestinal
diseases); if vitamin B12 was a component of a multivitamin supplement containing
additional substances beyond vitamin B9 and B6; or if they had a high risk of bias after full
text analysis (according to the Cochrane risk-of-bias tool, see quality assessment).
2.3. Study Selection, Quality Assessment, and Data Extraction
Title and abstract screening of all publications identified by the systematic literature
search was conducted independently by two reviewers (S.M. and J.M.B.). Subsequently, a
full text analysis for eligibility was performed. Disagreements were discussed and resolved
by consensus or with third party arbitration (T.R.).
To assess the quality of the included RCTs, we used the revised Cochrane risk-of-
bias tool for randomized trials (RoB 2) [53]. The study quality criteria included five
domains: risk of bias arising from the randomization process, risk of bias due to deviations
from the intended interventions (effect of assignment to intervention and of adhering to
intervention), missing outcome data, risk of bias in measurement of the outcome, and risk
of bias in selection of the reported result. Overall risk of bias judgement was evaluated as
follows: low risk of bias if all domains were judged to be of low risk, some concerns if at
least one domain was judged to raise some concerns but none to be at high risk, and high
risk of bias if at least one domain was judged to be at high risk or multiple domains were
judged to raise some concerns [53].
To assess the overall quality of evidence, we used the Grading of Recommendations
Assessment, Development, and Evaluation (GRADE) tool [54]. The assessment was based
on five key dimensions: risks of bias, inconsistency, indirectness, imprecision, and pub-
lication bias. The quality of the evidence was finally rated as high, moderate, low or
very low.
Relevant data for each included trial were extracted into a Microsoft Excel (2016)
spreadsheet (Microsoft Corporation, Redmond, WA, USA) by the first reviewer (J.M.B.),
which included sample size, standard baseline patient characteristics (age, sex, and blood
biochemical levels), doses of vitamin B12/B9/B6 and their administration frequency and
administration route, treatment and follow-up duration, and outcomes. Data that were pre-
sented in figures only were made numeric using the WebPlotDigitizer [55]. All entered data
were subsequently double-checked based on the original trials by a second reviewer (S.M.).
If a trial only reported the results of subgroups, an inquiry was sent to the corresponding
author to request data that were relevant for our systematic review analysis.
2.4. Outcomes
Primary endpoints were between-group differences on validated clinical tests measur-
ing cognitive function, depression, or fatigue.
2.5. Data Synthesis and Analysis
Sixty-two clinical tests were used to measure one of the three different outcome do-
mains, and many of them were only assessed in one or two trials. Cognitive function tests
often targeted highly specific functions, and thus, we aggregated them into four outcome
subdomains (cognitive executive, cognitive memory, cognitive global and cognitive speed)
to maintain adequate precision in the analysis. Tests assessing depression and fatigue were
Nutrients 2021, 13, 923 4 of 18
each categorized into one domain (depressive symptoms and idiopathic fatigue, respec-
tively). A short description of each clinical test can be found in Supplementary Table S2.
All analyses were conducted with R4.0.3 (R Foundation for Statistical Computing,
Vienna, Austria) [56].
For the meta-analysis, we gathered and standardized data for the primary endpoints
and calculated effect sizes (ES) as standardized mean differences (Hedges’ g) with respec-
tive confidence intervals (CI) in order to compare vitamin B12 interventions to placebos.
Computations were carried out with the package esc [57]. Due to the presence of multiple
outcome measures per study, we required meta-analysis models beyond the standard
random-effects model, as we could not assume that the outcomes within each study were
independent and estimated the same outcome. We, therefore, used three-level random-
effects (3LRE) models with random effects at the single study level and of single outcome
measures (the individual clinical tests) fitted with the package metafor [58]. For each
outcome, we performed two separate meta-analyses for each of the two different interven-
tion types (B12 alone and B complex) whenever more than one study was available and
one meta-analysis for the pooled effect of both treatments. To assess differences between
intervention types, subgroup analyses were carried out for outcomes encompassing at least
10 studies in mixed-effect models, using intervention type as a fixed-effect moderator, in
addition to the 3LRE models as described in [59]. Statistical significance of intervention
type was assessed by means of the t-test. The results of meta-analyses for the individ-
ual outcomes were summarized in forest plots showing the estimated summary effects
of B12 alone, the B complex, and the pooled effect of B12 treatments. Between-study
heterogeneity was reported in terms of the study-level random effect variance estimate
tau-squared (τ2) and the I-squared (I2) statistic, computed for 3LRE models using the
approach described in [60]. In addition, Cochran’s Q test was used to assess significance of
study-level heterogeneity.
Meta-regression models were used to explore associations of treatment effects with po-
tential moderators included as fixed effects within the 3LRE model framework. Moderators
included were baseline vitamin B12 serum levels, vitamin intervention (B12 alone or B com-
plex), duration of treatment, average bioavailable daily dose (assuming oral bioavailability
of 1% [28,61,62] and intramuscular bioavailability of 15% [63]), the interaction between
duration of treatment and average bioavailable daily dose, and population characteristics
(only patients without MCI (=no MCI), only patients with MCI (=MCI), or mixed popula-
tion samples (=no MCI to MCI)). We applied such meta-regression models when at least
10 studies for an outcome subdomain were available, following the recommendations by
the Cochrane handbook for systematic reviews of interventions [64].
To assess if our results were dependent on the choice of model and parameters, we
compared the aforementioned 3LRE model to a model based on robust variance estimation
(RVE) with a small sample size adjustment, using the package robumeta [65,66].
To assess the possibility of publication bias, we used funnel plots and Egger’s test [67].
To accommodate for multiple hypothesis testing, we set the p-value threshold for
statistical significance at 0.005 [68].
3. Results
3.1. Study Selection
As shown in Figure 1, 10,250 studies were retrieved by a systematic search and
this figure was reduced to 7016 studies after deduplication. Based on relevant titles and
abstracts, 53 studies were assessed in detail, applying inclusion and exclusion criteria as
well as criteria for the methodological quality.
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram. * ClinicalTrials.gov,
International Clinical Trials Registry Platform (ICTRP), EU Clinical Trial Register, and ISRCTN registry.
Two potentially eligible studies only reported the results of subgroup analyses [69,70].
Unfortunately, the corresponding authors were unable to provide us with the required data
of the intervention and control groups (e.g., number of patients in their subgroups low and
high tHcy and tertile 1–3, respectively) to calculate the ES and CI for the corresponding out-
comes. Therefore, we had to exclude these two studies from our systematic review. Further,
we had to exclude one pilot trial due to the high risk of bias after quality assessment [71].
Finally, 16 studies were eligible for our systematic review. The reasons for exclusion
are depicted in Figure 1 and in Supplementary Table S3.
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3.2. Overview and Characteristics of Included Studies
Of the 16 included studies, three investigated B12 alone versus a placebo [72–74],
twelve studied the B complex versus a placebo [75–86], and one study investigated B12
alone versus the B complex versus a placebo [87]. Therefore, the latter study contributed
separately to the B12 alone set as well as to the B12 complex set and counted as two studies
for further analysis. Further, three [75,84,85], two [76,82], and two [77,78] trials were each
based on the same study population; however, they contributed to different outcome
domains or analyzed different subgroups.
Table 1 shows the baseline characteristics of the included studies, divided into B12
alone and B complex groups. The publication years ranged from 1996 to 2019, the mean
age of the patients ranged from 66 to 82 years, the mean treatment duration ranged from
4 to 117 weeks, and the mean follow-up periods ranged from 8 to 117 weeks. Means
or medians of baseline vitamin B12 serum levels ranged from 186 to 385 pmol/L and
from 25.2 to 29.2 for the Mini-Mental State Examination (MMSE) scores. Further details
about the baseline and study characteristics of the included studies can be found in Sup-
plementary Tables S4 and S5. Fifteen trials administered vitamin B12 orally with dosage
ranges between 0.1 mg to 1 mg daily, and two intramuscularly with a dose of 1 mg once or
twice weekly.
3.3. Quality Assessment of Included Studies and Publication Bias
Supplementary Figure S1 shows the risk of bias of all included RCTs. Twelve trials
were found to have a low risk in all domains [72–77,80,82–86], five studies were judged
to raise some concerns in one or two domains [78,79,81,87], and one study was at overall
high risk (which was excluded before analysis) [71].
Results from the GRADE assessment are presented in Supplementary Table S6. The
four cognitive function outcome subdomains, as well as the depression domain were rated
as moderate quality.
We did not observe any asymmetries in the funnel plots for any cognitive function
outcome subdomain nor for the depression domain (Supplementary Figure S2).
3.4. Effects on Cognitive Function
In total, twelve studies reported effects on cognitive function, including four for B12
alone [72–74,87] and eight for the B complex [77,79,80,82–84,86,87]. Overall, we found no
evidence for an effect of B12 alone and B complex supplementation on any subdomain of
cognitive function outcomes. Even upon separate analyses of B12 alone or the B complex,
there was no evidence of an effect (Table 2, Figure 2; Figure 3, Supplementary Figures S3
and S4).
Meta-regression was performed for the cognitive subdomains measuring executive
functions and memory (Supplementary Table S7). Meta-regression showed no significant
associations of treatment effects with any of the potential predictors (baseline vitamin
B12 serum levels, vitamin intervention, duration of treatment, average bioavailable daily
dose, the interaction between duration of treatment and average bioavailable daily dose, or
population characteristics). Since four studies did not contain baseline vitamin B12 serum
levels, they were dropped from the full meta-regression model [78,81,83,86]. We explored
the data further and included the four studies by removing the factor of baseline B12 serum
level from the model, but the associations of the remaining factors with treatment effects
were essentially unchanged (Supplementary Table S7).
For the outcome subdomains: cognitive speed and cognitive global, not enough
studies (n = 8 and n = 7, respectively) were available for applying meta-regression models.
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Table 1. Patient characteristics at baseline of included studies.
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2000 25 daily, oral 104, 104 Cognitive
Kwok,
2020 [86]
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800 3 daily, oral 16.92, 16 Cognitive
McMahon,
2006 [80]
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Table 1. Cont.







































500 (500) 400 n.a. daily, oral 104, 104 Cognitive
van Uffelen,
2008 [83]
179 67 (37.4) 75.17 (n.a.) MCI
I: n.r.
P: n.r. 400 (500) 5000 50 daily, oral 52, 52 Cognitive
Walker,
2010 [85]
900 542 (60.2) 66.0 (4.3) No MCI I: 305.32 (151.05)P: 285.27 (105.77) 100 (100)
400 n.a. daily, oral 104, 104 Depression
Walker,
2012 [84]
900 542 (60.2) 66.0 (4.3) No MCI I: 305.32 (151.05)P: 285.27 (105.77) 100 (100)
400 n.a. daily, oral 104, 104 Cognitive
DDD: daily defined dose; DS: depressive symptoms; MCI: mild cognitive impairment. a median [IQR]; b median [range]; c with antidepressant; d extensive cognitive tests subsample.
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Table 2. Effects on cognitive function and depression.
Outcome
(sub)Domain
Effect Size 95% CI LB 95% CI UB I2 τ2 p-Value
Vitamin B12 Alone
Cognitive executive 0.09 −0.09 0.28 9.7% 0.0082 0.40
Cognitive memory 0.04 −0.19 0.26 41.7% 0.0355 0.34
Cognitive global 0.02 −0.17 0.21 6.3% 0.0018 0.56
Cognitive speed −0.10 −0.23 0.04 0% 0 0.84
Depression n.a. n.a. n.a. n.a. n.a. n.a.
Vitamin B Complex
Cognitive executive 0.06 −0.03 0.15 14.9 0.0015 0.87
Cognitive memory 0.03 −0.01 0.07 0.0 0 1.00
Cognitive global 0.07 0.00 0.13 0.0 0 0.93
Cognitive speed −0.08 −0.25 0.10 43.4 0.0149 0.68
Depression −0.03 −0.12 0.06 15.2 0.0026 0.56
Pooled (Vitamin B12 and Vitamin B Complex)
Cognitive executive 0.06 −0.021 0.141 13.1 0.0007 0.82
Cognitive memory 0.028 −0.011 0.067 0.0 0 0.98
Cognitive global 0.061 −0.001 0.123 0.0 0 0.95
Cognitive speed −0.081 −0.175 0.013 13.9 0.0037 0.88
Depression −0.049 −0.146 0.047 22.5 0.0044 0.50
LB: lower bound; UB: upper bound; n.a.: not applicable.
3.5. Effects on Depressive Symptoms
Effects on depressive symptoms were reported by six studies including one for B12
alone [73] and five for the B complex [75,76,78,85]. We found no overall effect of vitamin
supplementation on measures of depression as well as not for B complex separately (Table 2,
Figure 4).
A meta-analysis estimate for B12 alone and a meta-regression model were not possible
due to insufficient data.
3.6. Effects on Idiopathic Fatigue
Only one study investigating the B complex reported effects on idiopathic fatigue [81].
Therefore, neither a meta-analysis estimate nor a meta-regression model were possible.
Interestingly, the authors reported a statistically significant effect of vitamin B12 compared
to placebo on the vitality subscale of the SF-36 survey only at the end of the follow-up
period (8 weeks). Moreover, there was already a statistically significant difference at
baseline between the two groups with higher starting scores (=better) in the placebo group.















Figure 2. Forest plot for effects on cognitive executive function. CDT: Clock Drawing Test; CFT: Category Fluency Test;
COWAT: Controlled Oral Word Association Test; SCWT: Stroop Color–Word Test; SCWT-A: Stroop Color–Word Test
Abridged; VFT: Verbal Fluency Test; WAIS: Similarities Wechsler Adult Intelligence Scale.
3.7. Sensitivity Analyses
Due to the difficulty of modeling the potentially correlated outcome measures from
each study, in addition to the 3LRE model, we considered the RVE model to explore
sensitivity to model and parameter choice of our results. We fitted each of the two models
using a variety of correlation parameters to the outcomes of cognitive and depression tests.
We found that the RVE model was completely insensitive to correlation parameter choice
and had similar point estimates to the 3LRE model but wider confidence intervals.
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Figure 3. Forest plot for effects on cognitive memory function. AVLT: Auditory Verbal Learning Test; CPAL: Continuous
Paired Associates Learning; CVLT: California Verbal Learning Test; DCT: Digit Cancellation Test; ISLT: International
Shopping List Test; RAVLT: Rey Auditory Verbal Learning Test; TICS-M: Telephone Interview for Cognitive Status Modified.
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Figure 4. Forest plot for effects on depressive symptoms. † with antidepressant; †† without antidepressant. BDI: Beck
Depression Inventory; HDRS: Hamilton Depression Rating Scale; K10: Kessler Psychological Distress Scale; MDI: Major
Depression Inventory; MCS: PHQ-9: Patient Health Questionnaire 9.
4. Discussion
4.1. Main Findings
In this study, we included 16 RCTs with low risks of bias, testing vitamin B12 sup-
plementation in patients without advanced neurological disorders. The largest part of
the available evidence concerned the effectiveness of vitamin B12 supplementation in
subdomains of cognitive function. The meta-analysis found no effect of vitamin B12 sup-
plementation on any of these subdomains. For depressive symptoms, the meta-analysis
also showed no treatment effects. Regarding fatigue, the paucity of available high-quality
evidence precludes robust conclusions at this time.
4.2. Relation to Previously Published Systematic Reviews
Previously published systematic reviews investigating the effects of B12 alone or B
complex supplementation on cognitive function included studies performed in patients
with advanced neurological disorders [33–50]. This complicated the real world applicability
of the results because it was unclear as to which patients they applied, especially when
considering that the majority of patients with mental aliments do not suffer from advanced
neurological disorders. Thus, our study now contributes information that applies to a
large proportion of patients. Furthermore, almost three quarters of the previous reviews
also included trials that exclusively investigated folic acid or vitamin B6, introducing
heterogeneity not only at the patient level but also at the treatment level.
All previous reviews, except two, found no evidence in favor of B vitamin supplemen-
tation and were, thus, in line with our own results. A very recently published meta-analysis
by Suh et al. [48] reported beneficial effects for global cognition and episodic memory,
which is in particularly stark contrast to our meta-analysis. Additionally, from including
heterogeneous patient populations, the meta-analysis by Suh et al. also included studies
with heterogeneous interventions. Most importantly, however, results based heavily on
two studies, from which one was non-randomized [88] and the other was not placebo-
controlled [89], introduce a high risk of bias. Another meta-analysis published in 2013 also
found moderate beneficial effects on memory [42] but rests on only pooling results from
two studies.
Only one previous systematic review exists on the effects of B vitamins on depres-
sion [51]. This systematic review also found no evidence in favor of B vitamin supplemen-
tation, but many trials included only patients with major depressive episodes, hampering
the applicability of results because of heterogeneity at the patient level. In our study we
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excluded trials targeted at patients with major depression, reducing the heterogeneity and
increasing the applicability to predominantly less severely depressed patients.
4.3. Strengths and Limitations
To the best of our knowledge, this is the most extensive systematic review and meta-
analysis, including only high-quality RCTs that investigated the effect of vitamin B12 in the
absence of advanced neurological disorders on cognitive function, depressive symptoms,
and fatigue. The strengths of this systematic review are its applicability to large segments of
the general population. In this context, it is important to consider that significant amounts
of vitamin B12 prescriptions are currently given to patients with normal vitamin B12 serum
levels [32]. Second, no other systematic review and meta-analysis used meta-regression
analysis to explore potential determinants of the effectiveness of B12 supplementation,
such as treatment duration and dose. Third, this is the first systematic review to assess
vitamin B12 supplementation for idiopathic fatigue and our comprehensive literature
review showed that very little high-quality evidence is available on this topic. While this
scarcity of evidence hindered the meta-analysis, it also strongly contrasted with popular
beliefs and claims from marketing campaigns suggesting the effectiveness of vitamin B12
supplementation for fatigue. Ultimately, we used the GRADE tool to assess the overall
quality of the evidence.
One limitation of this study is the potentially large time difference between the onset
of vitamin B12 supplementation and the appearance of measurable benefits. Currently,
available RCTs, however, cover treatment durations of up to two years and, therefore, the
question of the effectiveness of long-term vitamin B12 supplementation remains unan-
swered due to the lack of experimental evidence. Another limitation of this study originates
from the remaining heterogeneity of included trials. While our inclusion criteria reduced
the clinical baseline heterogeneity of patient populations, we nevertheless encountered
trials reporting multiple outcomes for which one cannot assume independence, and, there-
fore, standard random-effects models are inadequate. Statistical modeling in this domain
is still under development and best practices have not yet been established. Therefore, we
implemented two different models to account for dependence between outcomes within
studies and explored model dependency of effect estimates. This sensitivity analysis
showed that our conclusions were robust for model choice. As there were no outliers
among the included trials, the statistical heterogeneity was very small, which adds to
the credibility of our pooled effect estimates [90]. Moreover, even if we excluded studies
investigating vitamin B12 replacement in pernicious anemia or other forms of clinically
relevant vitamin B12 deficiency, some individuals in the included trials might still have
suffered from such conditions because these are sometimes difficult to diagnose and only a
minority of included trials formally excluded such patients. Likewise, vitamin B12 levels
alone are of limited predictive value for vitamin B12 deficiency and comprehensive base-
line estimates more precisely determine vitamin B12 deficiency (including homocysteine,
methylmalonic acid and holotranscobalamin) were only used by a minority of the RCTs
included in this study. Our data are, therefore, potentially contaminated by individuals not
receiving vitamin B12 “supplementation” but rather “replacement” due to them indeed
being vitamin B12 deficient. Such a contamination, however, would have biased our results
in the direction of the effectiveness of vitamin B12 supplementation because in deficient
individuals, beneficial effects of vitamin B12 are more likely to occur. Therefore, our finding
of the lack of effectiveness remains unchallenged by this particular source of bias. Lastly, it
must be highlighted that this systematic review was exclusively concerned with vitamin
B12 supplementation in individuals without overt vitamin B12 deficiency and also in
general primary care populations without specific risk factors for vitamin B12 malnutrition,
such as meat-free diets. The role of vitamin B12 replacement in vitamin B12 deficiency, as
well as vitamin B12 supplementation in the risk of malnutrition, such as in vegan diets is
not addressed in this systematic review.
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4.4. Controversies Raised by This Study
Vitamin B12 supplementation continues to be a popular treatment even in patients
without overt vitamin B12 deficiency [32]. Many reasons may contribute to this popularity
of vitamin B12 supplementation, and in addition to expecting some specific—albeit weak—
effects, vitamins are popular for use as placebo interventions in cases where no other
treatment options are available [91]. Such liberal use of vitamin B12 supplementation,
however, might encounter criticism in the light of recent observational studies linking
vitamin B12 supplementation or serum levels with hip fractures [92], lung cancer [93,94],
and all-cause mortality in the general population [95].
4.5. Future Research
In the context of cognitive functioning and depressive symptoms, this systematic
review suggests that there is a low likelihood that future studies of similar design will
overturn the aggregated evidence. Since the longest treatment duration investigated was
two years, the most significant knowledge gap seems to concern long-term vitamin B12
supplementation. Interestingly, for fatigue, there is currently only one RCT of high quality
and there is, thus, room for future studies to fill this knowledge gap. Moreover, the role
of vitamin B12 supplementation could still be better understood in increasingly popular
meat-free diets.
5. Conclusions
This systematic review, focusing on vitamin B12 supplementation for elderly patients
with normal or subclinical vitamin B12 serum levels and without advanced neurological
disorders, found high-quality evidence for the absence of treatment effects on cognitive
functioning and depressive symptoms. For idiopathic fatigue, this literature review de-
tected a paucity of evidence. Taken together, the findings from this systematic review
discourage vitamin B12 supplementation for cognitive function and depressive symptoms.
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